Single User
£3188
PDF
40 pages

Primary Myelofibrosis (PMF) Forecast in 8 Major Markets 2016-2026


Primary Myelofibrosis (PMF), also known as myelofibrosis, myeloid metaplasia or chronic idiopathic myelofibrosis, is part of the collection of diseases known as myeloproliferative neoplasms (MPNs). PMF is a chronic blood cancer that affects the haematopoietic system, causing progressive fibrosis of the bone marrow and impairs the ability of new blood cell production. Eventually, the bone marrow is unable to produce blood cells, and the spleen and liver take over the function causing abdominal swelling and discomfort.

This report provides the current prevalent population for PMF across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of PMF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PMF include:

  • Portal hypertension
  • Thrombosis
  • Anaemia
  • Gout
  • Extramedullary haematopoiesis
  • Leukocytosis
  • Splenomegaly
  • Acute myeloid leukaemia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global PMF’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of PMF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on PMF’s prevalent population.
  • Identify sub-populations within PMF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of PMF patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Primary Myelofibrosis
  • Features of PMF Patients
    • Staging and Scores of PMF
    • Cell Counts in PMF Patients
    • Associated Conditions of PMF
    • JAK2 Mutation in PMF Patients
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Prevalence of PMF, total (000s)
  • Prevalence of PMF, males (000s)
  • Prevalence of PMF, females (000s)
  • Dupriez score in PMF patients, total (000s)
  • Bone marrow staging in PMF patients, total (000s)
  • White blood cell count (x 109 /dL) in PMF patients, total (000s)
  • Platelet count (x 109 /dL) in PMF patients, total (000s)
  • Circulating blasts (%) in PMF patients, total (000s)
  • Hepatomegaly in PMF patients, total (000s)
  • Spleen size (cm) below the costal margin in PMF patients, total (000s)
  • Incidence of thrombosis, total (000s)
  • Thrombosis outcome in patients, total (000s)
  • Prevalence of JAK2-VG17F mutation, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of PMF by 5-yr age cohort, males (000s)
  • USA Prevalence of PMF by 5-yr age cohort, females (000s)
  • France Prevalence of PMF by 5-yr age cohort, males (000s)
  • France Prevalence of PMF by 5-yr age cohort, females (000s)
  • Germany Prevalence of PMF by 5-yr age cohort, males (000s)
  • Germany Prevalence of PMF by 5-yr age cohort, females (000s)
  • Italy Prevalence of PMF by 5-yr age cohort, males (000s)
  • Italy Prevalence of PMF by 5-yr age cohort, females (000s)
  • Spain Prevalence of PMF by 5-yr age cohort, males (000s)
  • Spain Prevalence of PMF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of PMF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of PMF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of PMF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of PMF by 5-yr age cohort, females (000s)
  • Japan Prevalence of PMF by 5-yr age cohort, males (000s)
  • Japan Prevalence of PMF by 5-yr age cohort, females (000s)
Brazil, France, Germany, Italy, Japan, Spain, United Kingdom, United States of America